The investors include, Small Cap World Fund, Neuberger Berman Emerging Market Equity Fund, Fundsmith Emerging Equities Trust Plc and First State Indian Sub Continent Fund among others.
The company is looking to sell 13,685,095 shares through the IPO.
Of these, promoter Sushil Shah will sell 6,272,335 shares, while investor CA Lotus Investments, a subsidiary of US-based private equity firm Carlyle Group will offload 7,412,760 shares.
The price band has been fixed in the range of Rs 877-880 per share.
Metropolis’ revenue from operations rose at a CAGR of 16.3 per cent to Rs 643.6 crore from FY16 to FY18, while its profits rose at a CAGR of 15.7 per cent to Rs 109.7 crore. The company is debt free.
Metropolis has presence across 19 states and a leadership position in West and South India through its network of 83 clinical laboratories, 1,473 patient touch points and 396 ARCs (assisted referral centres) in the regions.